Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 12.73% and Operating profit at 9.34% over the last 5 years
2
The company has declared Positive results for the last 6 consecutive quarters
3
With ROE of 13.37%, it has a attractive valuation with a 1.54 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 3,804 Million (Small Cap)
15.00
NA
1.31%
0.00
13.37%
1.69
Revenue and Profits:
Net Sales:
458 Million
(Quarterly Results - Mar 2026)
Net Profit:
78 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-13.1%
0%
-13.1%
6 Months
-18.3%
0%
-18.3%
1 Year
1.1%
0%
1.1%
2 Years
147.84%
0%
147.84%
3 Years
37.43%
0%
37.43%
4 Years
11.19%
0%
11.19%
5 Years
-34.56%
0%
-34.56%
HVSEN Biotechnology Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
12.73%
EBIT Growth (5y)
9.34%
EBIT to Interest (avg)
13.19
Debt to EBITDA (avg)
1.93
Net Debt to Equity (avg)
0.32
Sales to Capital Employed (avg)
0.51
Tax Ratio
11.79%
Dividend Payout Ratio
22.47%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
5.06%
ROE (avg)
4.83%
Valuation key factors
Factor
Value
P/E Ratio
15
Industry P/E
Price to Book Value
1.99
EV to EBIT
14.20
EV to EBITDA
11.03
EV to Capital Employed
1.98
EV to Sales
2.58
PEG Ratio
0.02
Dividend Yield
0.37%
ROCE (Latest)
13.97%
ROE (Latest)
13.37%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
458.20
421.70
8.66%
Operating Profit (PBDIT) excl Other Income
89.70
104.40
-14.08%
Interest
1.80
1.50
20.00%
Exceptional Items
-8.80
-5.20
-69.23%
Consolidate Net Profit
78.20
65.00
20.31%
Operating Profit Margin (Excl OI)
195.80%
175.10%
2.07%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is 8.66% vs -3.57% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 20.31% vs -8.32% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
1,679.30
1,198.20
40.15%
Operating Profit (PBDIT) excl Other Income
398.00
130.50
204.98%
Interest
14.10
43.00
-67.21%
Exceptional Items
2.20
-24.00
109.17%
Consolidate Net Profit
253.50
-19.80
1,380.30%
Operating Profit Margin (Excl OI)
165.30%
14.40%
15.09%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 40.15% vs 17.71% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 1,380.30% vs -217.86% in Dec 2024
About HVSEN Biotechnology Co., Ltd. 
HVSEN Biotechnology Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






